NCT03216486View on ClinicalTrials.gov

An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 31, 2017

Primary Completion Date

November 1, 2018

Study Completion Date

November 1, 2018

Conditions
Osteogenesis Imperfecta
Interventions
DRUG

BPS804

IV administration of BPS804 in 5% Dextrose solution

Trial Locations (2)

77030

Mereo Investigator Site, Houston

87106

Mereo Investigator Site, Albuquerque

Sponsors

Collaborators (1)

Mereo BioPharma
All Listed Sponsors
collaborator

Mereo BioPharma

INDUSTRY

lead

Ultragenyx Pharmaceutical Inc

INDUSTRY

NCT03216486 - An Exploratory Study of BPS804 Treatment in Adult Patients With Type I, III or IV Osteogenesis Imperfecta | Biotech Hunter | Biotech Hunter